Pouchitis Clinical Trial
Official title:
To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study)
Patients with a bowel condition called ulcerative colitis have bowel surgery in which a portion of their bowel is removed and the reconnected at the small bowel to the anus. Sometimes, after the surgery, this connection part, the pouch, would be inflamed in a condition called Acute Pouchitis. Physicians usually treat them by prescribing antibiotics; however, some patients do not respond and need additional surgery. In this study, we will test an alternative treatment for this complication by performing manuka honey enemas twice a day for 30 days. This is a pilot study and ten patients will undergo enema treatment.
Pouchitis is the most common long-term complication of ileal pouch-anal anastomosis (IPAA)
in ulcerative colitis (UC). Pouchitis is defined as a clinical syndrome of watery, frequent,
at times bloody stool accompanied by urgency, incontinence, abdominal cramps, malaise, and
fever. The PDAI (Pouchitis Disease Activity Index) provides a standardized definition of
pouchitis based on clinical, endoscopic, and histological markers. Pouchitis is defined as a
score ≥ 7 and remission as a score < 7. Recently, the modified Pouchitis Disease Activity
Index has been used to omit biopsy and histology from the standard PDAI. Omission of
endoscopic biopsy and histology from the PDAI simplifies pouchitis diagnostic criteria,
reduces the cost of diagnosis, and avoids delay associated with determining histology score,
while providing equivalent sensitivity and specificity. Patients with acute pouchitis are
managed routinely by antibiotics such as Ciprofloxacin and Metronidazole. This treatment has
some side effects, is expensive, and fails to respond in some patients. Some patients who
are unresponsive to antibiotic therapy will need to have a pouchectomy and ileostomy done.
On the other hand, multiple studies have shown that honey, especially manuka honey has
anti-inflammatory, anti-bacterial, wound healing, and anti-ulcerous effects. Phenolic
compounds in honey, such as flavonoids, have been reported to exhibit a wide range of
biological activities, including antibacterial, antiviral, anti-inflammatory, antioxidant,
antitumor, anti-allergic, and vasodilatory actions. This honey can clear infection, remove
malodour, reduce inflammation and pain, cause edema and exudation to subside, and increase
the rate of healing by stimulation of angiogenesis, granulation and epithelialization.
Due to problems associated with antibiotic therapy, such as side effects, cost and failure
of some patients to respond, we are looking to find an alternative method for treating acute
pouchitis. This study is designed to determine the effect of manuka honey on symptoms, signs
and pathology of acute pouchitis patients. We will select patients with any of the signs and
symptoms of pouchitis, such as abdominal pain, fever, frequency or urgency of defecation.
Proctoscopy will be done before and after honey enema and the modified PDAI scores will be
determined. The manuka honey enema will be administered twice a day, for one month. Then,
the modified PDAI scores before and after completion of honey enema treatment of these
patients, will be compared.
We know that bacterial overgrowth, ischemia, faecal stasis, recurrence of ulcerative colitis
in the pouch, or possibly a novel third form of inflammatory bowel disease, are possible
etiologies of pouchitis. We also know that manuka honey has anti-inflammatory and
anti-bacterial properties. Some studies demonstrate that honey is effective in the treatment
of induced colitis in animal models. However, there is no current literature on the effect
of honey on colitis or pouchitis in humans. Based on the aforementioned properties of honey,
and considering the probable etiologies of pouchitis, we expect that these patients will
respond to this method of treatment.
Some research has been done on the effect of honey in the treatment of colitis in animal
models, but there have been no clinical studies that have assessed this treatment in
pouchitis, or even colitis, in humans. Considering the etiologies of pouchitis, such as
inflammation and bacterial overgrowth, and considering the main effects of honey, such as
anti-bacterial and anti-inflammatory efficacy, honey enema may be useful in the treatment of
pouchitis. Our study is trying to determine the effect of manuka honey enema in the
treatment of acute pouchitis. We will try to determine whether the honey enema helps to
decrease inflammation and infection in the pouch, and thereby provide us with a safe
alternative method for the treatment of pouchitis.
In this pilot study, we will select patients who have any of the signs and symptoms of acute
pouchitis, such as abdominal pain, fever, frequency, or urgency of defecation. Proctoscopy
will be performed on these patients. Ten patients with modified PDAI score ≥ 7 will receive
honey enemas twice a day for one month. We chose a twice daily enema regimen, because
patients with inflammatory bowel disease usually receive their enemas twice a day. We expect
one month to be enough time, because the duration of antibiotic therapy for patients with
acute pouchitis is about one month. Then, the PDAI score of these patients, before and after
honey enema will be compared.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04979832 -
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05829109 -
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
|
Early Phase 1 | |
Recruiting |
NCT03136419 -
Microbiota and Immune microEnvironment in Pouchitis
|
N/A | |
Withdrawn |
NCT04640155 -
Treating Chronic Pouchitis With a Low FODMAP Diet
|
N/A | |
Completed |
NCT02790138 -
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
|
Phase 4 | |
Not yet recruiting |
NCT01202396 -
The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis
|
N/A | |
Completed |
NCT02428361 -
Fecal Microbiota Transplant (FMT) for Pouchitis
|
Early Phase 1 | |
Completed |
NCT03538366 -
Fecal Microbiota Transplantation for Chronic Pouchitis
|
N/A | |
Completed |
NCT04763564 -
Efficacy of Liraglutide Therapy in Patients With IPAA
|
Phase 2 | |
Terminated |
NCT00583531 -
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
|
Phase 2 | |
Recruiting |
NCT03524352 -
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
|
Phase 3 | |
Completed |
NCT04820413 -
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
|
N/A | |
Not yet recruiting |
NCT06443502 -
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
|
Phase 3 | |
Recruiting |
NCT04089345 -
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
|
Phase 3 | |
Not yet recruiting |
NCT03526796 -
Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis
|
N/A | |
Terminated |
NCT02782325 -
Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)
|
Phase 1/Phase 2 | |
Completed |
NCT02828410 -
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
|
N/A | |
Recruiting |
NCT05578313 -
Inflammatory Bowel Diseases (IBD) Cannabis Registry
|
||
Not yet recruiting |
NCT06316999 -
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
|
N/A |